We recently compiled a list of the 12 Stocks That Will Double in 2025. In this article, we are going to take a look at where ...

The trial is anticipated to enrol 462 subjects and aims to confirm the safety and efficacy of the combination.

The Phase III trial builds on findings from prior findings that indicated Anktiva can restore T-cell function and improve overall survival in patients with advanced of metastatic non-small cell lung ...

Mutual Advisors LLC bought a new position in ImmunityBio, Inc. (NASDAQ:IBRX – Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC).

ImmunityBio shares were up 14% to $3.52 after the company entered into a collaboration and supply agreement with BeiGene. The two companies will conduct a confirmatory randomized Phase 3 clinical ...

In this article, we will take a look at the 12 stocks that will double in 2025.

ImmunityBio (IBRX) announced the European Medicines Agency has accepted for review and begun assessing the marketing authorization application ...

ImmunityBio shares surged as much as 14% on Wednesday, reaching their highest level in nearly seven weeks while lifting ...

CULVER CITY, Calif., January 29, 2025--ImmunityBio, Inc. (NASDAQ: IBRX) today announced it has entered into a collaboration and supply agreement with BeiGene, Ltd. (to be changed to BeOne ...

Sidney, a book developer and publisher, announced today the publication of YOU ARE THE DOCTOR: The Importance of a Team Approach in Cancer Treatment by the late Susan Finlay Dunbar, MD. A unique ...

BCS is proud to announce its inclusion in Inc.'s annual Best in Business list, which celebrates the exceptional achievements and contributions of companies that have made a profound impact on their ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...